"In a broad-ranging draft guidance published May 2
Post# of 145570
![Avatar](/images/ProfileImages/424989898_3046_Avatar jpeg2.jpg)
Also of interest:
"stakeholders are largely welcoming the guidance, but are asking the agency to re-examine several aspects, including allowing more flexibility in clinical trial design and loosening the recommendation that participant information be stored at a physical location."
From an article about decentralizing clinical trials. Warning: if you click the link, you will use up one of your 4 free articles. This site is affiliated with Feuerstein so there is NO way I will pay for a subscription.
https://endpts.com/phrma-walgreens-mayo-clini...-guidance/
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)